{"id":"inm004","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for INM004 are limited in public literature, as a Phase 3 candidate from Inmunova S.A., it is likely an immunomodulatory or checkpoint-related therapeutic. The exact molecular target and mechanism require access to clinical trial protocols or company disclosures.","oneSentence":"INM004 is an immunotherapeutic agent designed to modulate immune responses, likely through activation or enhancement of anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:24.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06389474","phase":"PHASE3","title":"Efficacy of INM004 in Children With STEC-HUS","status":"RECRUITING","sponsor":"Inmunova S.A.","startDate":"2024-10-05","conditions":"Hemolytic-Uremic Syndrome","enrollment":220},{"nctId":"NCT05569746","phase":"PHASE2","title":"A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS","status":"COMPLETED","sponsor":"Inmunova S.A.","startDate":"2022-10-06","conditions":"Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease, Hemolytic-Uremic Syndrome","enrollment":57},{"nctId":"NCT04132375","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS","status":"TERMINATED","sponsor":"Inmunova S.A.","startDate":"2019-07-17","conditions":"Bloody Diarrhea, STEC, Unspecified, Hemolytic-Uremic Syndrome","enrollment":11},{"nctId":"NCT03388216","phase":"PHASE1","title":"Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers","status":"COMPLETED","sponsor":"Inmunova S.A.","startDate":"2017-12-16","conditions":"Healthy Volunteers","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Active","Equine immunoglobulin fragment F(ab')2 anti-Shiga toxin","active"],"phase":"phase_3","status":"active","brandName":"INM004","genericName":"INM004","companyName":"Inmunova S.A.","companyId":"inmunova-s-a","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}